Abstract
To overcome the poor dissolution of telmisartan (TMS) at weak acidic pH, amorphous alkalinized TMS (AAT) was prepared by introducing sodium hydroxide as a selective alkalizer. AAT-containing polymeric solid dispersions were prepared by a solvent evaporation method; these solid dispersions were AAT-PEG, AAT-PVP, AAT-POL, and AAT-SOL for the polymers of PEG 6000, PVP K30, Poloxamer 407, and Soluplus, respectively. The characteristics of the different formulations were observed by differential scanning calorimetry, powder X-ray diffraction, Fourier transform infrared spectroscopy, and scanning electron microscopy. To compare the supersaturation behavior, a dissolution test was performed at 37 ± 0.5 °C either in 900 ml (plain condition) or 500 ml (limited condition) of pH 6.8-simulated intestinal fluid used as a medium. AAT-SOL exhibited enhanced dissolution, indicating the probability of extended supersaturation in the limited condition. AAT-SOL was further formulated into a tablet by introducing other excipients, Vivapur 105 and Croscarmellose, as a binder and superdisintegrant, respectively, using a direct compression method. The selected AAT-SOL tablet was superior to Micardis (the reference product) in the aspect of supersaturation maintenance during dissolution in the limited condition, suggesting that it is a promising candidate for practical development that can replace the commercial product in the future.
Similar content being viewed by others
References
Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, Palesch Y, Albers GW, Bath P, Bornstein N, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New Engl J Med 2016;359:1225–1237.
Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000;28:149–67.
Zhang Y, Jiang T, Zhang Q, Wang S. Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property. Eur J Pharm Biopharm. 2010;76:17–23.
Tran PHL, Tran HTT, Lee BJ. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J Control Release. 2008;129:59–65.
Antoncic L, Copar A. U.S. patent application no. 11 2009;718, 838.
Zhong L, Zhu X, Yu B, Su W. Influence of alkalizers on dissolution properties of telmisartan in solid dispersions prepared by cogrinding. Drug Dev Ind Pharm. 2014;40:1660–9.
Kothawade SN, Kadam NR, Aragade PD, Baheti DG. Formulation and characterization of telmisatan solid dispersions. Int J Pharmtech Res. 2010;2:341–7.
Park J, Cho W, Cha KH, Ahn J, Han K, Hwang SJ. Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process. Int J Pharm. 2013;441:50–5.
Siepe S, Lueckel B, Kramer A, Ries A, Gurny R. Strategies for the design of hydrophilic matrix tablets with controlled microenvironmental pH. Int J Pharm. 2006;316:14–20.
Riis T, Bauer-Brandl A, Wagner T, Kranz H. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur J Pharm Biopharm. 2007;65:78–84.
Marasini N, Tran TH, Poudel BK, Cho HJ, Choi YK, Chi SC, et al. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique. Int J Pharm. 2013;441:424–32.
Choi JS. Enhanced stability and solubility of pH-dependent drug telmisartan achieved by solid dispersion. J Drug Deliv Sci Technol. 2017;37:194–203.
Yamashita S, Fukunishi A, Higashino H, Kataoka M, Wada K. Design of supersaturable formulation of telmisartan with pH modifier: in vitro study on dissolution and precipitation. J Pharm Investig. 2017;47:163–71.
Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GG, Taylor LS. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci. 2011;100:3316–31.
Mahapatra AK, Murthy PN, Biswal S, Mahapatra AP, Pradhan SP. Dissolution enhancement and physicochemical characterization of valsartan in solid dispersions with β-CD, HP β-CD, and PVP K-30. Dissolut Technol. 2011;18:39–45.
Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm. 2003;267:79–91.
Qian F, Huang J, Hussain MA. Drug–polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci. 2010;99:2941–7.
Xu S, Dai WG. Drug precipitation inhibitors in supersaturable formulations. Int J Pharm. 2013;453:36–43.
Phuong HLT, Tran TTD, Lee SA, Nho VH, Chi SC, Lee BJ. Roles of MgO release from polyethylene glycol 6000-based solid dispersions on microenvironmental pH, enhanced dissolution and reduced gastrointestinal damage of telmisartan. Arch Pharm Res. 2011;34:747–55.
Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47–60.
Shah S, Joshi S, Lin S, Madan PL. Preparation and characterization of spironolactone solid dispersions using hydrophilic carriers. Asian J Pharm Sci. 2012;7:40–9.
Oh DH, Kang JH, Kim DW, Lee BJ, Kim JO, Yong CS, et al. Comparison of solid self-microemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier. Int J Pharm. 2011;420:412–8.
Kane R, Kuchekar B. Preparation, physicochemical characterization, dissolution and formulation studies of telmisartan cyclodextrin inclusion complexes. Asian J Pharm. 2010;4:52.
Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 2009;5:259–93.
Ozaki S, Minamisono T, Yamashita T, Kato T, Kushida I. Supersaturation–nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms. J Pharm Sci. 2012;101:214–22.
Sangwal K. Additives and crystallization processes: from fundamentals to applications. Chichester: John Wiley & Sons Ltd; 2007.
Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98:2549–72.
Li DX, Han MJ, Balakrishnan P, Yan YD, Oh DH, Joe JH, et al. Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound. Arch Pharm Res. 2010;33:95–101.
Warren DB, Benameur H, Porter CJ, Pouton CW. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J Drug Target. 2010;18:704–31.
Patel B, Parikh RH, Swarnkar D. Enhancement of dissolution of telmisartan through use of solid dispersion technique-surface solid dispersion. J Pharm Bioallied Sci. 2012;4(Suppl 1):64.
Cao Y, Shi LL, Cao QR, Yang M, Cui JH. In-vitro characterization and oral bioavailability of organic solvent-free solid dispersions containing telmisartan. Iran J Pharm Res. 2016;15:385.
Nagarsenker MS, Meshram RN, Ramprakash G. Solid dispersion of hydroxypropyl β-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. J Pharm Pharmacol. 2000;52:949–56.
Kumar SGV, Mishra DN. Analgesic, anti-inflammatory, and ulcerogenic studies of meloxicam solid dispersion prepared with polyethylene glycol 6000. Methods Find Exp Clin Pharmacol. 2006;28:419.
Craig DQ. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231:131–44.
Dukeck R, Sieger P, Karmwar P. Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective. Eur J Pharm Sci. 2013;49:723–31.
Karavas E, Ktistis G, Xenakis A, Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur J Pharm Biopharm. 2006;63:103–14.
Hong JY, Kim JK, Song YK, Park JS, Kim CK. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release. 2006;110:332–8.
Herting MG, Kleinebudde P. Roll compaction/dry granulation: effect of raw material particle size on granule and tablet properties. Int J Pharm. 2007;338:110–8.
Kiran T, Shastri N, Ramakrishna S, Sadanandam M. Surface solid dispersion of glimepiride for enhancement of dissolution rate. Int J Pharmtech Res. 2009;1:822–31.
Patil AB, Ramchandra VK, Dhananjay SS, Trushali SK, Bhaskar BG, Vivek SK, et al. Formulation and evaluation of solid dispersion of telmisartan with KOH as alkaliser by hot melt method. J Pharm Biomed Sci. 2010;1:1–7.
Cirri M, Maestrelli F, Mennini N, Mura P. Influence of the preparation method on the physical–chemical properties of ketoprofen–cyclodextrin–phosphatidylcholine ternary systems. J Pharm Biomed Anal. 2009;50:690–4.
Funding
This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2016R1A2B4011449). This work also supported in part by the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare, Republic of Korea (HI17C0710), and the Advanced Technology Center program (10051950) funded by the Ministry of Trade, Industry and Energy (MI, Korea).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chae, J.S., Chae, B.R., Shin, D.J. et al. Tablet Formulation of a Polymeric Solid Dispersion Containing Amorphous Alkalinized Telmisartan. AAPS PharmSciTech 19, 2990–2999 (2018). https://doi.org/10.1208/s12249-018-1124-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-018-1124-y